Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2

Adamas Pharmaceuticals (Nasdaq:ADMS) announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the long-term, ongoing Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, were published online in Movement Disorders Clinical Practice.

As quoted in the press release:

“We continue to collect and analyze data from our EASE LID 2 open-label Phase 3 clinical trial, as we further characterize the benefits and risks of GOCOVRI,” said Rajiv Patni, MD, Chief Medical Officer of Adamas Pharmaceuticals, Inc. “We look forward to completing the study and reporting topline findings in the second quarter of 2018.”

Click here to read the full press release.